ACE2 and COVID-19: On the other hand, a recent COVID-19 related study showed decreased expression of ACE in combination with increases in ACE2 likely causing bradykinin-related increases in vascular dilation, vascular permeability and hypotension, explaining many of the symptoms being observed in COVID-19 [40].